SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
PHILADELPHIA, Jan. 26, 2016 -- Medgenics, Inc. (NYSE MKT:MDGN), today announced that members of its management team will participate in the 2016 Canaccord Genuity Rare Disease, BioPharma One-On-One Day on Tuesday, February 2, 2016 in New York, NY.
About Medgenics, Inc.
Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the Company's website at www.medgenics.com.
Contacts: Medgenics, Inc. Brian Piper [email protected]
